Literature DB >> 1810193

Long-term protection of polyaspartic acid in experimental gentamicin nephrotoxicity.

S K Swan1, S J Kohlhepp, P W Kohnen, D N Gilbert, W M Bennett.   

Abstract

Polyaspartic Acid (PAA) protects the kidney from experimental gentamicin nephrotoxicity despite large increases in renal cortical gentamicin content. In these experiments, prominent cytoplasmic vacuoles were noted in all animals that received PAA with or without gentamicin. The present study showed that there were no renal structural or functional consequences of PAA given alone or with gentamicin for up to 14 days, followed by a 16-week washout period. Creatinine clearance was similar to that of controls in animals that received gentamicin and in those that received PAA alone. Thus, complete functional protection was conferred by PAA and gentamicin, confirming previous reports from our laboratory. There was no protection by PAA from the nephrotoxic effects of mercuric chloride and cis-platinum.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810193      PMCID: PMC245436          DOI: 10.1128/AAC.35.12.2591

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Light and electron microscopic changes in proximal tubules of rats after administration of glucose, mannitol, sucrose, or dextran.

Authors:  A B MAUNSBACH; S C MADDEN; H LATTA
Journal:  Lab Invest       Date:  1962-06       Impact factor: 5.662

2.  Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid.

Authors:  D Beauchamp; G Laurent; P Maldague; S Abid; B K Kishore; P M Tulkens
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

3.  Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phospholipid layers in vitro.

Authors:  B K Kishore; Z Kállay; P Lambricht; G Laurent; P M Tulkens
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

4.  Inhibition of renal membrane binding and nephrotoxicity of gentamicin by polyasparagine and polyaspartic acid in the rat.

Authors:  P D Williams; G H Hottendorf
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1985-02

5.  Reduction of gentamicin nephrotoxicity by the concomitant administration of poly-l-aspartic acid and poly-l-asparagine in rats.

Authors:  D Beauchamp; G Laurent; P Maldague; P M Tulkens
Journal:  Arch Toxicol Suppl       Date:  1986

6.  Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function.

Authors:  J English; A Evan; D C Houghton; W M Bennett
Journal:  Transplantation       Date:  1987-07       Impact factor: 4.939

7.  Polyaspartic acid protects against gentamicin nephrotoxicity in the rat.

Authors:  L S Ramsammy; C Josepovitz; B P Lane; G J Kaloyanides
Journal:  J Pharmacol Exp Ther       Date:  1989-07       Impact factor: 4.030

8.  Controlled comparison of gentamicin and tobramycin nephrotoxicity.

Authors:  G R Matzke; R L Lucarotti; H S Shapiro
Journal:  Am J Nephrol       Date:  1983 Jan-Feb       Impact factor: 3.754

9.  Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides.

Authors:  P D Williams; G H Hottendorf; D B Bennett
Journal:  J Pharmacol Exp Ther       Date:  1986-06       Impact factor: 4.030

10.  Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity.

Authors:  D N Gilbert; C A Wood; S J Kohlhepp; P W Kohnen; D C Houghton; H C Finkbeiner; J Lindsley; W M Bennett
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

  10 in total
  7 in total

1.  Effect of polyaspartic acid on pharmacokinetics of gentamicin after single intravenous dose in the dog.

Authors:  T Whittem; K Parton; K Turner
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.

Authors:  Dan Wang; Valery Belakhov; Jeyakumar Kandasamy; Timor Baasov; Su-Chen Li; Yu-Teh Li; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2011-10-19       Impact factor: 4.797

Review 3.  Suppression of premature termination codons as a therapeutic approach.

Authors:  Kim M Keeling; Dan Wang; Sara E Conard; David M Bedwell
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-06-07       Impact factor: 8.250

4.  Pharmacologic limits of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity.

Authors:  S K Swan; D N Gilbert; S J Kohlhepp; P W Kohnen; W M Bennett
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

5.  Duration of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity.

Authors:  S K Swan; D N Gilbert; S J Kohlhepp; J E Leggett; P W Kohnen; W M Bennett
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

6.  Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity.

Authors:  N Thibault; L Grenier; M Simard; M G Bergeron; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

7.  A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation.

Authors:  Tobias Goldmann; Nora Overlack; Fabian Möller; Valery Belakhov; Michiel van Wyk; Timor Baasov; Uwe Wolfrum; Kerstin Nagel-Wolfrum
Journal:  EMBO Mol Med       Date:  2012-10-02       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.